Glad to see Enodia featured in European Biotechnology Magazine, highlighting our approach to targeting protein translocation. https://lnkd.in/ga6PryGe
Enodia Therapeutics
Recherche en biotechnologie
Targeting protein degradation at the point of synthesis
À propos
Enodia Therapeutics is a French biotech company building a proprietary small-molecule platform that selectively modulates the SEC61 translocon, a central control point of the protein secretion pathway. By intervening at the point of synthesis, Enodia redirects disease-driving secreted and transmembrane proteins toward early degradation, before they mature or exert pathological effects, while preserving normal cellular function. Leveraging a deep, well-characterized chemical space of SEC61 inhibitors, together with proteomics and machine-learning–guided drug design, Enodia enables highly selective, upstream intervention across multiple indications, starting with inflammatory and autoimmune diseases.
- Site web
-
https://www.enodiatx.com/
Lien externe pour Enodia Therapeutics
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 1 employé
- Siège social
- Paris
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2025
Lieux
-
Principal
Obtenir l’itinéraire
75007 Paris, FR
Employés chez Enodia Therapeutics
Nouvelles
-
Great to see Enodia’s Seed financing and scientific approach featured in an exclusive Endpoints News story.
Exclusive: French startup Enodia has collected about $24 million in seed funding from Pfizer Ventures and others. The protein degrader biotech uncorked the same week as another European protein degrader (Dark Blue Therapeutics) was acquired by Amgen. Enodia Therapeutics CEO Yves Ribeill, a three-decade biotech veteran, analogized the startup’s approach to fixing issues with a product on a factory floor instead of once it’s out the door. It’s an alternative to “having to block that compound a little bit later in the recalling step, once the protein has been excreted outside of the cell,” he said. Backers of the one-year-old biotech also include Elaia, Bpifrance, Wallonie Entreprendre, MACSF, InvestSud, Sambrinvest and Mission BioCapital. The money will get Enodia to two autoimmune and inflammatory disease drug candidates. A Series A would then carry those experimental medicines into human testing. The only direct competitor, Ribeill said, is California biotech Gate Bioscience, which is allied with Lilly. #enodiatherapeutics #enodia #sec61 #seedfunding #biotechfunding #parisbiotech #proteindegrader https://lnkd.in/gtZppEsa
-
We are proud to share that Enodia Therapeutics has secured €20.7M in seed financing to advance our small-molecule platform for targeted protein degradation at the point of synthesis. This financing supports the continued development of our approach to selectively modulating the SEC61 translocon, intervening upstream, before disease-driving secreted and membrane proteins can exert their effects. We’re grateful for the strong support from our investors, led by Elaia, Pfizer Ventures, and Bpifrance Life Sciences Venture (InnoBio), with participation from Wallonie Entreprendre, Argobio Studio, MACSF, Institut Pasteur, INVESTSUD, Sambrinvest, and Mission BioCapital. This milestone reflects confidence in the science, the platform, and the team, and enables us to accelerate toward our next phase of discovery and development. Thank you to everyone who has contributed to building Enodia. Read the release: https://lnkd.in/e_mbv9c2 #TargetedProteinDegradation #Translocon #UpstreamBiology #BiologyFirst #Biotech #SEC61
-
-
Looking back at 2025 ! For Enodia, this year was about building : less about visibility, more about getting the foundations right. Thank you to everyone who contributed to this phase : for the thoughtful discussions, the trust, and the commitment. 2026 will be about turning this work into first concrete outcomes. More to come ! ✨ Wishing you all a restful holiday season and all the best for the year ahead. ✨ #TargetedProteinDegradation #SmallMolecules #Proteomics #InflammatoryDiseases
-
-
Last week, Enodia Therapeutics had the pleasure of joining the Bio Investment Convention 2025, hosted by Sambrinvest, alongside some of the most promising biotech innovators in Wallonia. Events like this are essential in bridging scientific excellence and investment : a full day of sharp discussions, thoughtful investors, and eight biotech teams pitching We were proud to present our work in targeted protein degradation and to connect with peers and investors who share our ambition to bring transformative science to patients. Many thanks to Sambrinvest and all partners involved for driving such a strong and forward-looking initiative. #BIC #Wallonie #TPD #TargetedProteinDegradation #Translocon #Inflammation #Autoimmunity #Sec61 #Enodia #Argobio #Pasteur
-
-
A nice read in POCmedia (in French, subscribers only!) on how Enodia Therapeutics combines AI-driven screening with Sec61-targeted protein degradation to design next-generation therapies for inflammatory and autoimmune diseases. Grateful for this overview of our work. 👉 Read more: https://lnkd.in/eGYg7yTa #TPD #TargetedProteinDegradation #Translocon #Inflammation #Autoimmunity #Sec61 #Enodia #Argobio #Pasteur
-
We’re thrilled to see our science highlighted. A big thank you to C&EN for the feature.
Paris-based Enodia Therapeutics has launched out of France’s Pasteur Institute and the Argobio Studio to design small molecules that strategically throw a wrench in the processing of undesired proteins.
-
🔬 Unveiling the Translocon to unlock innovative therapies 🔬 We are thrilled to announce the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to blocking and degrading disease-causing proteins for the treatment of cancer, inflammatory diseases, and viral infections. Born from pioneering research at Institut Pasteur and supported by Argobio Studio, Enodia Therapeutics is developing small molecules to selectively inhibit the Translocon—an essential gateway for protein secretion. By leveraging generative AI, we are designing next-generation inhibitors paving the way for transformative therapies. 🏆 A key milestone in our journey: Enodia Therapeutics is very honored to be awarded the Pfizer x BioLabs France 2025 Golden Ticket, a prestigious recognition that will accelerate our mission and grant us privileged access to the BioLabs ecosystem. 👏 Huge congratulations to Yves Ribeill, CEO of Enodia, Pr Caroline Demangel, cofounder of Enodia Therapeutics and the entire Enodia team for this exciting achievement! We are just getting started, and we look forward to collaborating with the biotech and pharma community to bring innovative treatments to patients. 📢 Want to learn more? Read our press release and let’s connect!: https://home.enodiatx.com/ #targetedproteindegradation #Sec61 #translocon Dr Isabelle Buckle, Michel PEREZ, Hélène Asnagli, Liliane GOETSCH . PhD, Aurore Hick